AL
Alvotech
ALVOW · NASDAQ
$0.30 +0.00% (+$0.00)
1M -6.19%
Market Cap $93.9M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.4
33.2% upside
Current Price
$0.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALVOW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
0/9Valuation
100 /100
Cheap P/S 0.19x
P/FCF N/A
P/B N/A
Growth
100 /100
Growing Rev. growth 91.85%
FCF growth N/A
Book val. growth N/A
Profitability
32 /100
Weak FCF margin 61.03%
Op. margin 9.62%
Gross margin 60.45%
Quality
63 /100
Average ROA 11.31%
Asset turnover 0.31x
ROIC 20.17%
Debt
35 /100
Moderate Int. coverage -0.22x
Current ratio 1.65x
Net debt/EBITDA N/A
Stability
13 /100
Unstable Profitable years 1
EPS volatility 52.56%
Beta 0.19x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALVOW
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Lisa Graver
Employees
1,460
Headquarters
Luxembourg
Upcoming events
11 NOV
Earnings
Upcoming earnings report